Zacks Investment Research upgraded shares of QUIDEL CORP (QDEL) from NEUTRAL to OUTPERFORM on October 23, 2014, with a target price of $29.10.
Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on QUIDEL CORP (QDEL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment